TOPIRAMATE APPLICATION IN COMPLEX TREATMENT OF EPILEPSY
Abstract
Topiramate (Topamax®) is one of the most widely used modern anti-epileptic drugs (AED) in Russia. This is primarily due to the broad spectrum of activity of this drug. Its mechanism of action is complex and includes several components. It was shown that all main mechanisms of epilepsy development are within the pharmacological targets of this drug, which makes it distinguished among other AED. The drug is efficient in both focal and generalized forms of epilepsy. The following adverse effects of treatment may possibly develop: fatigability, thought disorder, headache and confused mental state. It should be borne in mind that the majority of adverse effects disappeared spontaneously in the course of treatment. Such adverse effects as reduction of body weight and nephrolithiasis generally occurred as long-term side effects of treatment.
About the Authors
O. L. Badalyan
GOU VPO Russian State Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
A. A. Savenkov
GOU VPO Russian State Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
K. H. Taisheva
GOU VPO Russian State Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
O. Yu. Tertyshnik
GOU VPO Russian State Medical University named after N.I. Pirogov
Russian Federation
Russian Federation
References
1. Зенков Л.Р. Алгоритмы выбора препаратов в лечении фокальной эпилепсии // РМЖ – 2004. – Т.12. – № 5. – С.270–275.
2. Зенков Л.Р. Лечение эпилепсии у детей. – РМЖ. – 2007. – T. 15. – № 10. – C. 789.
3. Мухин К.Ю., Глухова Л.Ю., Петрухин А.С. и др. Топамакс при монотерапии эпилепсии // Журн. неврол. психиат. – 2004. – т. 104, № 8. – С. 35–40.
4. Abou–Khalil B. Topiramat in the long–term management of refractory epilepsy // Epilepsia. – 2000. –v.41, suppl. 1. – P. S72–S76.
5. BenMenachem E. Clinical efficacy of topiramate as addon therapy in refractory partial epilepsy: the European experience // Epilepsia 1997 V0l.38 (Suppl.1) P.S28 S30.
6. Biton V. Preliminary openlabel experience with topiramate in primery generflized seizures // Epilepsia Vol.38, (Suppl.1) P.S42 S44.
7. Brodie M. Do we need any more new antiepileptic drugs? // Epilepsy Research 2001 Vol.45 P.36.
8. Brown S., Wolf H.,Swinyard E. et al.The novel anticonvulsant topiramate enhances GABAmediated chlorid flux // Epilepsia 1993 Vol.34 (Suppl.2) P.122123.
9. BurcetDarde J., GarciaRibas G., GomezArguelles, J. Topiramat monotherapy and evaluation of plasma levels [Abstract] // Neuroscience in action: from clinical dilemma to the therapeutic breakthrough, poster abstract Hamburg, Germany,2223 March 2002 P.188.
10. Chadwick D. An overview of the efficacy and tolerability of new antiepileptic drugs // Epilepsia 1997 Vol.38 (Suppl.1) P.S59S62.
11. Easterling D., Zakszewski T., Moyer M. et al. Plasma pharmacokinetics of topiramate, a new anticonvulsant in humans [Abstract] // Epilepsia 1988 Vol.29 P.662.
12. Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience // Epilepsia 1997 V0l.38 (Suppl.1) P.S24 S27.
13. French J. Clinical efficacy of new antiepileptic drugs in refractory partial epilepsy: experience in the United States with three novel drugs // Epilepsia 1996 Vol.37 (Suppl.) P.S23S26.
14. Maryanoff B., Margul B. Topiramate //Drugs Future 1989Vol.14 P.324.
15. Meldrum B. Mechanisms of action of newer antiepileptic drugs [Abstract] // Topiramate: Closing the therapeutic gap in epilepsy 3 September 1996 / Astracts of symposium in conjunction with the second European Congress of epileptology P.2.
16. Montouris G., Biton V.,Rosenfeld W. et al. Nonfocal generalized tonicclonic seizures: response during longterm topiramate treatment // Epilepsia 2000 Vol.41,(Suppl.1) P.S77S81.
17. Petrukhin A. & Mukhin K. Topamax (topiramate) in childhood epilepsy: efficacy and tolerability (the pilot stydy) [Abstract] // // Neuroscience in action: from clinical dilemma to the therapeutic breakthrough, poster abstract Hamburg, Germany, 2223 March 2002 P. 217.
18. Privitera M.,Finchman R., Penry J. et al. Topiramate placebocontrolled dose ranging trial in refractory partial epilepsy using 600, 800, and 1000mg daily dosages // Neurology 1996 Vol.46, June P.178 1683.
19. Reife R., Pledger G. Topiramate as adjunctive therapy in refractory partial epilepsy: pooled analysis of data from five doubleblind, placebocontrolled trials // Epilepsia 1997Vol.,38, (Suppl.1) P.S31S33.
20. Reife R., Pledger G., ShuChen Wu. Topiramate as addon therapy: pooled analysis of randomized controlled trials in adults // Epilepsia 2000Vol.41 (Suppl.1) P.S66S71.
21. Rogawski M., Porter R. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds // Pharmacological Review 1990 Vol.42 P.223286.
22. Rosenfeld W., Liao S., Kramer L. et al. Comparison of steadystate pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy// Epilepsia 1997 Vol.38, ?3 P.324333.
23. Rosenfeld W., Sachdeo R., Faught R. et al. Longterm experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of openlabel treatment // Epilepsia 1997 Vol.38, (Suppl.1) P.S34S36.
24. Sachdeo R., Reife R., Lim P. et al. Topiramate monotherapy for partial onset seizures // Epilepsia 1997 Vol.38, ?3 P.294 300.
25. Sachdeo R., Sachdeo S., Walker S. et al. Steadystate pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy // Epilepsia 1996 Vol.37 P.774780.
26. Sander J. Practical aspects of the use of topiramate in patients with epilepsy// Epilepsia 1997 Vol.38, (Suppl.1) P.S56S58.
27. Shorvon S., Stefan H. Overview of the Safety of newer antiepileptic drugs // Epilepsia 1997 Vol.38 (Suppl.1) P.S45 S51.
28. Tassinarri C., Michelucci R., Chauvel P. et al. Doubleblind placebocontrolled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy // Epilepsia 1996 Vol.37, ?8 P.763768.
29. Wu W., Heebner J., Streeter A. et al. Evaluation of the absorption, excretion pharmacokinetics and metabolism of the anticonvulsant topiramate in healthy men [Abstract] // Pharm. Res. 1994 Vol.11 (Suppl.) P.336.
Review
For citations:
Badalyan O.L., Savenkov A.A., Taisheva K.H., Tertyshnik O.Yu. TOPIRAMATE APPLICATION IN COMPLEX TREATMENT OF EPILEPSY. Epilepsy and paroxysmal conditions. 2010;2(1):25-29. (In Russ.)
Views: 443
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
